Cancer treatment and research communications最新文献

{"title":"Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R","authors":"Ben Markman ,&nbsp;Steven Kao ,&nbsp;Nick Pavlakis ,&nbsp;Victoria Bray ,&nbsp;Leisl Packer ,&nbsp;Shankar Siva","doi":"10.1016/j.ctarc.2025.100929","DOIUrl":"10.1016/j.ctarc.2025.100929","url":null,"abstract":"<div><h3>MicroAbstract</h3><div>Australian subset of the multicentric PACIFIC-R study (NCT03798535) in patients with unresectable, stage III non-small cell lung cancer without progression following chemoradiotherapy, found a median progression-free survival of 22.4 months (95% confidence interval, 17.5 to 30.8) confirming clinical benefit of durvalumab consolidation post-chemoradiotherapy in the real-world setting.</div></div><div><h3>Introduction</h3><div>The Phase 3 PACIFIC trial established post-chemoradiotherapy (CRT) durvalumab consolidation as standard treatment for patients with unresectable, stage III non-small cell lung cancer (NSCLC). We present the results from the Australian subset of the multicentric PACIFIC-R study (NCT03798535) assessing the effectiveness of durvalumab in the real-world setting.</div></div><div><h3>Patients and Methods</h3><div>Patients with unresectable, stage III NSCLC without progression following CRT, receiving at least 1 dose of durvalumab (10 mg/kg intravenously, every 2 weeks) through an early access program (EAP) between September 2017 and December 2019, were enrolled. Primary endpoints, progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan–Meier method.</div></div><div><h3>Results: As of February 7, 2022, 165 patients (median age</h3><div>67.0 years) with a median follow-up of 34.7 months were enrolled. Most received last radiation ≥42 days before durvalumab initiation (126, 79.2%) at a dose of 54 to 60 Gy (141, 88.7%). Median PFS was 22.4 months (95% confidence interval [CI], 17.5 to 30.8). The 3-year PFS and OS rates were 38.9% (95% CI, 31.0 to 46.7) and 59.1% (95% CI, 51.2 to 66.2). Pneumonitis was the most frequent adverse events of special interest (27, 16.4%); which led to treatment discontinuation in 19 (11.5%) patients.</div></div><div><h3>Conclusion</h3><div>The real-world results from the Australian PACIFIC-R subset confirm translation of the clinical benefit of post-CRT durvalumab consolidation in the pivotal PACIFIC trial to the real-world setting, showing favorable survival outcomes, irrespective of delays in durvalumab initiation post-radiation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100929"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatic-based study to investigate the fluctuations and performance of MYD88 and GRB2 gene expression in gastric cancer; Can they be considered diagnostic biomarkers?","authors":"Seyed Mustafa Mirnezami ,&nbsp;Saman Morovat ,&nbsp;Afshin Shafaghi ,&nbsp;Seyedeh Elham Norollahi ,&nbsp;Kourosh Delpasand ,&nbsp;Kosar Babaei ,&nbsp;Ali Ashraf ,&nbsp;Ali Akbar Samadani","doi":"10.1016/j.ctarc.2025.101006","DOIUrl":"10.1016/j.ctarc.2025.101006","url":null,"abstract":"<div><div>Gastric cancer (GC) ranks as the fourth most prevalent malignancy and constitutes the second leading cause of cancer-related mortality globally. The elevated mortality rate is linked to molecular heterogeneity, late-stage diagnosis, and the limited efficacy of existing therapies. Recent developments in bioinformatics have facilitated the discovery of new biomarkers and therapeutic targets, essential for enhancing diagnosis, prognosis, and treatment approaches in gastric cancer. This study examines the bioinformatics analysis of two significant genes, GRB2 (Growth factor receptor-bound protein 2) and MYD88 (Myeloid differentiation primary response 88), associated with gastric cancer progression and immune response regulation.</div><div>We analyzed data from public databases such as GEPIA2, TIMER, GeneMANIA, and Cytoscape to examine the differential expression of GRB2 and MYD88 in gastric cancer tissues versus normal tissues, their roles in protein-protein interaction networks, and their association with immune infiltration. The findings indicate that elevated GRB2 expression correlates significantly with tumor invasion, underscoring its potential as an independent prognostic marker and therapeutic target in gastric cancer. The expression of MYD88 is associated with the activation of the NF-κB signaling pathway, which is induced by Helicobacter pylori infection, thereby contributing to chronic inflammation and tumorigenesis.</div><div>Functional enrichment analysis, encompassing KEGG and GO, indicated that both genes are involved in essential oncogenic pathways, such as cell proliferation, immune response regulation, and inflammatory signaling. The results indicate that GRB2 and MYD88 may function as significant biomarkers for patient stratification and should be considered in the formulation of targeted therapies for gastric cancer.</div><div>This study highlights the importance of GRB2 and MYD88 in the progression of gastric cancer and proposes their potential as therapeutic targets to enhance patient outcomes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 101006"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies","authors":"Derangula Lavanya ,&nbsp;VelugotlaPranathi Prasanna ,&nbsp;Asma Firdous ,&nbsp;Sneha Thakur","doi":"10.1016/j.ctarc.2025.100938","DOIUrl":"10.1016/j.ctarc.2025.100938","url":null,"abstract":"<div><div>Chemotherapy-induced nausea and vomiting (CINV) affects up to 80 % of cancer patients, significantly impacts the health in terms of their quality of life and straining healthcare resources. CINV is categorized into anticipatory, acute, and delayed types. Risk factors include younger age, female sex, a history of CINV, and the emetogenic potential of the chemotherapy agents. Drugs like cisplatin and anthracycline-cyclophosphamide combinations are highly emetogenic and pose the greatest risk. Advances in managing CINV include evidence-based guidelines and the use of antiemetic medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids. These measures have reduced vomiting incidents, but complete control of nausea remains challenging. Up to 60 % of patients still experience delayed nausea, and anticipatory nausea and vomiting affect up to 30 % and 20 % of patients, respectively, by the fourth treatment cycle. Clinical and alternative therapies are though effective, research suggests integrated management for CINV. Tailored approach is needed as it has both psychological and physiological influence. To overcome the challenges, the guidelines and antiemetic regimens should be improved according to individual patient evaluation and awareness is necessary. Research is ongoing to develop targeted therapies that combine pharmacological and behavioral interventions to improve CINV management, especially for patients who do not respond well to current antiemetic treatments.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100938"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategies","authors":"Heidi A. Abouzeid ,&nbsp;Loay Kassem ,&nbsp;Xuemei Liu ,&nbsp;Ahmed Abuelhana","doi":"10.1016/j.ctarc.2025.100918","DOIUrl":"10.1016/j.ctarc.2025.100918","url":null,"abstract":"<div><div>Breast cancer (BC) is one of the leading causes of cancer-related deaths among women worldwide. Paclitaxel (PTX), a chemotherapeutic agent derived from the taxane family, is commonly used in treating BC due to its ability to disrupt microtubule dynamics and induce cell death. However, resistance to PTX presents a significant challenge, as it diminishes the drug's effectiveness and can lead to treatment failure. This review explores the mechanisms by which PTX exerts its effects and the various factors contributing to resistance. These factors include genetic mutations that affect tubulin dynamics, the role of non-coding RNAs, molecular pathways involved in chemoresistance, epigenetic changes, post-transcriptional modifications, increased activity of ABC transporters that promote drug efflux, immunosuppressive interactions within the tumor microenvironment, and resistance mediated by autophagy. This review also explores strategies to overcome PTX resistance, including molecular and genetic innovations, combination therapies, and nanotechnology-based approaches. These strategies may improve PTX efficacy and enhance treatment outcomes for BC patients.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100918"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143808384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer","authors":"Kibum Kim ,&nbsp;Sakil Syeed ,&nbsp;Trang Au ,&nbsp;Amber Diaz ,&nbsp;Matthew B. Schabath ,&nbsp;Amanda Cass ,&nbsp;Richard Hall ,&nbsp;Lori Pai ,&nbsp;Chenghui Li ,&nbsp;Nicole Balmaceda ,&nbsp;Alison Palumbo ,&nbsp;Autumn Carey ,&nbsp;Mumtu Lalla ,&nbsp;Matthew Henry ,&nbsp;Diana Brixner ,&nbsp;David Stenehjem","doi":"10.1016/j.ctarc.2025.100898","DOIUrl":"10.1016/j.ctarc.2025.100898","url":null,"abstract":"<div><h3>Purpose</h3><div>Osimertinib is a third-generation EGFR-TKI and preferred first-line (1L) treatment for <em>EGFR</em> positive (<em>EGFR+</em>) metastatic non-small cell lung cancer (mNSCLC). This study compared real-world clinical outcomes of 1L osimertinib versus 1st or 2nd generation EGFR-TKIs (1/2G-TKIs) in patients with EGFR+ mNSCLC.</div></div><div><h3>Methods</h3><div>Nine academic cancer centers in the US participated in the retrospective cohort study. Patients aged ≥18 years with <em>EGFR+</em> mNSCLC and treated with 1L EGFR-TKI were included. Clinical outcomes included real-world progression-free survival (rwPFS), duration of treatment (DOT), time to next treatment (TTNT), central nervous system incidence-free survival (CNS-IFS), and overall survival (OS). Multivariable regression models were used to control for differences in patient characteristics (<em>p</em> &lt; 0.1) between the osimertinib and 1/2G-TKI cohorts.</div></div><div><h3>Results</h3><div>The study included 181 osimertinib patients and 171 1/2G-TKI patients. Osimertinib had a longer rwPFS compared to 1/2G-TKIs (median PFS, 95 % confidence interval [CI]: 16.2 months (13.2–19.7) vs. 10.8 months (9.5–12.7); hazard Ratio [HR], 95 % CI: 0.60 (0.44–0.82). DOT and TTNT were significantly longer in patients treated with osimertinib versus 1/2G-TKI (HR, 95 % CI: 0.51 (0.38–0.68) for DOT; 0.54 (0.39–0.74) for TTNT). The respective HR point estimate for CNF-IFS and OS of 0.62 and 0.83 preferred osimertinib. However, small patient counts and number of events posed challenges in drawing conclusion regarding the significance of the delayed CNS-IFS or OS.</div></div><div><h3>Conclusion</h3><div>Patients treated with osimertinib had a prolonged time to progression and longer time maintain the treatment compared to 1/2G-TKI. This real-world evidence is aligned with clinical trial results.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100898"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer","authors":"Mathias H. Gramkow ,&nbsp;Camilla S. Mosgaard ,&nbsp;Jakob V. Schou ,&nbsp;Ellen Hein Nordvig ,&nbsp;Troels Gammeltoft Dolin ,&nbsp;Jakob Lykke ,&nbsp;Dorte L. Nielsen ,&nbsp;Per Pfeiffer ,&nbsp;Camilla Qvortrup ,&nbsp;Mette K. Yilmaz ,&nbsp;Ole Larsen ,&nbsp;Stig E. Bojesen ,&nbsp;Benny V. Jensen ,&nbsp;Julia S. Johansen","doi":"10.1016/j.ctarc.2025.100907","DOIUrl":"10.1016/j.ctarc.2025.100907","url":null,"abstract":"<div><h3>Background</h3><div>Carcinoembryonic antigen (CEA) is the only prognostic circulating biomarker used in clinical practice for recurrence free (RFS), progression free (PFS) and overall survival (OS) in patients with colorectal cancer (CRC). Not all CRC tumors express this protein and carbohydrate antigen (CA)19–9 has been proposed as an adjunctive in prognostication. We aimed to test if CA19–9 yielded additional information to CEA regarding prognosis.</div></div><div><h3>Patients and methods</h3><div>We included 886 patients with CRC across eight clinical cohorts. Preoperative serum samples were collected from 376 patients with stage I-III CRC and from 510 with metastatic (m)CRC before 1st (<em>n</em> = 233)^, 3rd (<em>n</em> = 178) and 3rd/4th (<em>n</em> = 99) line chemotherapy. CA19–9 and CEA were determined by routine assays, the values were log-2 transformed and entered as variables in Cox regression models with RFS (stage I-III), PFS and OS as the outcomes, adjusted for age, sex, and site of primary tumor and mutual adjustment between CA199 and CEA. Random effects meta-analyses were conducted for stage I-III,1st line, and 3rd/4th line mCRC cohorts separately.</div></div><div><h3>Results</h3><div>Meta-analyses showed that higher pre-treatment CA19–9 and CEA were associated with shorter RFS (CA19–9: hazard ratio per doubling of concentration (HR)=1.20, 95 % confidence interval (CI) 1.05–1.38; CEA: HR=1.22, 95 % CI 1.05–1.41) in stage I-III CRC. Only higher CEA was associated with shorter OS in 1st line mCRC (HR=1.07, 95 % CI 1.00-1.07).</div></div><div><h3>Conclusion</h3><div>CA19–9 might aid in identifying patients with a high risk of recurrence after primary radical resection. Further studies are needed to validate these findings.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100907"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response of unilateral primary lacrimal sac diffuse large B-cell lymphoma treated without radiotherapy in an adult: A rare case report and review of the literature","authors":"Suzana Sultan ,&nbsp;Tasnim Ibrahim ,&nbsp;Ali Habib ,&nbsp;Firas Hussein","doi":"10.1016/j.ctarc.2025.100897","DOIUrl":"10.1016/j.ctarc.2025.100897","url":null,"abstract":"<div><div>Diffuse large B-cell lymphoma (DLBCL) manifests extranodally in one-third of non-Hodgkin lymphoma (NHL) cases. However, primary DLBCL of the lacrimal sac is very rare. A 54-year-old man presented with a 5-month history of right-sided epiphora. He visited three private clinics and was misdiagnosed with conjunctivitis. Later, a painless mass in the right lacrimal area prompted an MRI scan followed by a CT scan, which suggested a lacrimal sac mass. The mass was surgically excised, and histopathology and immunohistochemistry revealed DLBCL. A PET/CT scan was done instead of bone marrow biopsy, which excluded systemic lymphomatous involvement, confirming the diagnosis of primary right lacrimal sac DLBCL. The patient received six standard cycles of the R-CHOP regimen. Although no radiotherapy was used, CT findings after the completion of the 4th cycle showed a complete response (CR), which was maintained in a follow-up CT scan 2 months after chemotherapy completion. Despite the rarity of the tumor, it should be considered in the differential diagnosis of long-standing or unresponsive inflammatory conditions. Radiotherapy-free management could achieve CR in limited-stage DLBCL.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100897"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway","authors":"Yu Wang ,&nbsp;Yuting Wang ,&nbsp;Huabin Gao ,&nbsp;Lin Chen,&nbsp;Shuai Zheng,&nbsp;Yongyu Chen,&nbsp;Huijuan Shi,&nbsp;Anjia Han","doi":"10.1016/j.ctarc.2025.100899","DOIUrl":"10.1016/j.ctarc.2025.100899","url":null,"abstract":"<div><div>To investigate the effect and molecular mechanism of ezetimibe on colorectal cancer (CRC), our study found that ezetimibe significantly inhibited the proliferation and progression of CRC. Further study showed that RPS6KA2 might be the target gene of ezetimibe treatment on CRC. RPS6KA2 expression was significantly lower in human CRC tissue samples and associated with T classification and vascular invasion of tumor cells. RPS6KA2 inhibited proliferation, migration, and invasion of CRC cells. The underlying mechanisms indicated that interaction between RPS6KA2 and PCSK9 was observed within the cytoplasmic compartment of CRC cells. RPS6KA2 suppressed PCSK9 and MAPK signaling pathway in CRC cells. BI-D1780 which is an inhibitor of RPS6KA2 increased PCSK9 and MAPK signaling pathway related proteins expression in SW620 cells. However, an inhibitor or stimulator of MAPK did not affect RPS6KA2 and PCSK9 expression, respectively. In vivo, CRC cells with RPS6KA2 or PCSK9 overexpression could inhibit or promote tumor growth and metastasis, respectively. PCSK9 promoted proliferation, migration, and invasion of CRC cells. PCSK9 expression was higher in human CRC samples and associated with N classification and TNM stage of CRC. In conclusion, our study firstly suggests that ezetimibe suppresses CRC progression by upregulating RPS6KA2 while downregulating PCSK9/MAPK signaling pathway.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100899"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting lipid metabolism to overcome tamoxifen resistance in breast cancer: Evaluating the synergistic therapeutic potential of quercetin","authors":"Radwa M. Rifaat,&nbsp;Marwa W. Kamel,&nbsp;Marwa Sharaky,&nbsp;Yasmin M. Attia,&nbsp;Samia A. Shouman","doi":"10.1016/j.ctarc.2025.100953","DOIUrl":"10.1016/j.ctarc.2025.100953","url":null,"abstract":"<div><div>Breast cancer remains the most prevalent malignancy among women globally, with hormone receptor-positive subtypes representing the majority of cases. Despite significant advances in treatment, resistance to Tamoxifen, a cornerstone therapy for estrogen receptor-positive (ER⁺) breast cancer, poses a critical challenge, affecting up to 50 % of patients. Emerging evidence suggests that dysregulated lipid metabolism plays a pivotal role in breast cancer progression and therapy resistance. This systematic review aims to explore the intricate relationship between lipid metabolism and Tamoxifen resistance, with a particular focus on the potential therapeutic synergy of combining Tamoxifen with lipid metabolism modulators, such as Quercetin. We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library for studies published between 2000 and 2023, examining the role of lipid metabolic pathways in breast cancer and the impact of Quercetin on enhancing Tamoxifen efficacy. The findings suggest that targeting key enzymes involved in lipid metabolism, including fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), may impair cancer cell survival mechanisms and sensitize tumors to Tamoxifen. The combination of Tamoxifen and Quercetin appears to exhibit synergistic effects, enhancing apoptosis and reducing cell proliferation more effectively than either agent alone. This review highlights the potential of combining Tamoxifen with Quercetin as a therapeutic strategy to overcome Tamoxifen resistance, providing a rationale for further clinical trials to investigate this combination therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100953"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the oncologic outcomes of breast-conserving surgery for breast cancer patients performed either upfront or following neoadjuvant chemotherapy: a matched retrospective cohort","authors":"Hazem Assi ,&nbsp;Malak Ghezzawi ,&nbsp;Hussein Nassar ,&nbsp;Cynthia Alame ,&nbsp;Jason El Azzi ,&nbsp;Bashar Hassan ,&nbsp;Selim Gebran ,&nbsp;Melhem Nehme ,&nbsp;Zeina Hassan ,&nbsp;Ziad Salem ,&nbsp;Jaber Al-Abbas ,&nbsp;Eman Sbaity","doi":"10.1016/j.ctarc.2025.100984","DOIUrl":"10.1016/j.ctarc.2025.100984","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy (NACT) is used to reduce breast cancer size before surgery, allowing for breast conservation surgery (BCS) instead of mastectomy. However, concerns exist about higher positive margins and local recurrence rates.</div></div><div><h3>Aims</h3><div>This study compared the incidence of positive margins, local recurrence rates, and other oncologic outcomes of BCS performed either upfront or after NACT.</div></div><div><h3>Methods</h3><div>We conducted a retrospective matched cohort study of 122 patients treated at the American University of Beirut Medical Center between July 2011 and September 2016. Patients who underwent BCS whether upfront or after chemotherapy were matched 1:1 based on disease stage and molecular subtype.</div></div><div><h3>Results</h3><div>We matched 61 breast cancer patients treated with BCS following NACT to those treated with upfront BCS. Patients in the NACT group were younger, with a mean age of 45 years compared to 52 years in the upfront group. In the NACT group, 31 (51.7 %) have high-grade disease. Most patients received adjuvant radiation therapy. Positive margins were found in 14 patients in the NACT group and 5 in the upfront group (<em>p</em> = 0.03). Local recurrence was 8.6 % in the NACT group versus 1.7 % in the upfront group (<em>p</em> = 0.086). 5 years disease free survival was significantly lower 81 % in the NACT group versus 95 % in the upfront group (<em>p</em> = 0.03). Overall survival was not significantly different in the NACT group compared to the upfront group (<em>p</em> = 0.574).</div></div><div><h3>Conclusion</h3><div>Breast cancer treated with BCS after NACT has a low incidence of positive margins and similar oncologic outcomes compared to BCS performed upfront.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100984"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}